Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 705,000 |
| EBITDA | $-874.67M |
| Operating Margin | 0.00% |
| Return on Equity | -192.50% |
| Return on Assets | -101.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.79 |
| Price-to-Book | 21.69 |
| Price-to-Sales (TTM) | 3891.31 |
| EV/Revenue | 6425.28 |
| EV/EBITDA | -5.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $797.75M |
| Float | $152.28M |
| % Insiders | 80.89% |
| % Institutions | 17.43% |
Volatility is currently expanding
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading higher on Thursday after its development partner, Akeso Inc., reported highly favorable overall survival data from a late-stage clinical trial.
Summit Therapeutics is positioned as a high-conviction buy into the November 2026 FDA PDUFA decision for ivonescimab in NSCLC. SMMT's ivonescimab demonstrates robust PFS and statistically significant OS benefits in multiple Phase III trials, supporting best-in-class potential versus PD-1 monotherapy. Financials reflect intentional capital deployment, with $690M+ cash and 4–5 quarters of runway to fund late-stage clinical catalysts and regulatory milestones.
Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mu.
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). Thi.
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class investigational bispecific antibody ivonescimab, into urothelial carcinoma, or bladder cancer, with the initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial. Summit is starting a randomized Phase II/III clinical study, HARMONi-GU1, to evaluate ivonescimab plus the antibody-drug co.
Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically significant PFS but only a favorable trend in OS; updated data with a hazard ratio of 0.76 has been submitted. Competition is intensifying, with multiple large pharmas developing similar VEGF/PD-1 bispecifics; no acquisition or major partnership offers have materialized for SMMT.
NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SMMT and any ticker you trade — then tracks every position and per-strategy win rate.
